The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Evening
Inanaco is a good stock picker tho bud I wish I knew half of what he does check his history. Other than that good luck with your investments.
http://www.britishbulls.com/StockPage.asp?CompanyTicker=SLN&MarketTicker=Health%20Care&TYP=S Have recommended a sell.
Scancell Holdings (LON:SCLP), London’s best performing stock last year, is close to receiving patent approval in Japan for its ImmunoBody vaccine technology. It already has protection for its intellectual property in the US, Europe and Australia. Dr Richard Goodfellow, joint chief executive, said: "This is a further important step in the development and commercialisation of the ImmunoBody platform and provides further evidence to support the novelty of Scancell's ImmunoBody technology in another key pharmaceutical market. “Scancell will continue building its growing portfolio of intellectual property in parallel with driving the clinical trial programme on SCIB1 forward during 2013." Its drug candidate SCIB1 is being developed for melanoma. Shares in Scancell, which specialises in cancer vaccines, have advanced 775% in the last year.
Courtesy Pale_Rider UNDERSTANDING SCIB1 PHASE 1 All the patients who received the vaccine in SCIB1's Phase 1 trial were terminally ill with Stage 4 melanoma. Many would have been given just weeks to live by their doctor prior to entering the Phase 1 trial. Most would have been expected to die within 9 months from the time of their original diagnosis. Of course by the time they actually entered the trial this life expectancy would have been far less. Secondly SCIB1's Phase 1 trial was not intended as a treatment trial but as a test to determine whether or not the vaccine was safe. Therefore the trial was organized as a dose escalation study. To do this 11 patients were separated into groups. The first group was given only one tenth of the required dose of the vaccine. None of this group were expected to survive. The second group were given the vaccine at half strength and because they tolerated it well without serious side effects a final group was given the vaccine at its normal dose level. Although this trial was designed to test for safety and tolerability it also provided an opportunity to see what the clinical effects of the vaccine might be, especially on those who had received the full dose. Out of the first group of four patients who only received one tenth of the proper dose three died as would have been expected. These were entered into the trial starting June 2010. Nevertheless one of these patients is still alive. It is too early to know whether receiving such a low dose of the vaccine contributed to this patient's survival but to survive for so long is unusual. Out of the second group of three patients who received the vaccine at half the intended dose only one died and two patients actually responded to the vaccine even at half strength. Both these patients are still alive and one remains disease free more than a year following treatment. Out of the final group of four patients who were to receive the vaccine at full dose one unfortunately died shortly after admittance and was unable to be given four out of the five injections necessary for treatment. Those patients that were well enough to complete the full course at full strength are still alive and one of these remains disease free more than a year after starting the treatment.
You hope this is the bottom I spotted this at 2.14p and once it was 80p right.
Scancell is on the move. Long term trend is up as I said before.
Hi Bluerose. You have been attacking scancell for a while now and your predictions have been way off. I am glad I don't listen to you. What appears to be clear in my mind is scancell has a number of vaccines. Melanoma, lung, prostate and a couple of others we know about. Immunobody works looking at the way I interpret the rns. The vaccine is designed to combat cancer stage 1. Which does not require chemo because it is a platform which can be tweaked Against any form of cancer and stop tumour mass before it gets started. ( look at the people who had tumours surgical removed before treatment and whilst using the vaccine have not grown back). One of the reasons a big pharma will want scancell is that they are a threat to their existing and more costly treatments and does not require chemo.
http://uk.bannronn.com/stocks/trend-analysis.php?symbol=SCLP.L
http://uk.bannronn.com/stocks/trend-analysis.php?symbol=SLN.L
Scancell SCIb1 is starting to get noticed, they have 5 cancer vaccines now Looks like the Immunobody platform will be very big indeed and the company is up for sale" The Telegraph has spotted Scancell ... I wonder if Big Pharma has yet http://www.telegraph.co.uk/health/9482981/World-Cancer-Day-Are-we-killing-cancer.html GLA
Where did you put your money instead. ?. I am confident in sclp might be worth a look if you are confident in bio, good luck
Cheers M8
Do you use an ipad, as well as an iphone?. What network are you on.?
Has sold this one, Globo might be a better option.
I think the people selling out now will regret it. Okay they might of brought in at 24p but over the long term we should do well.